Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease

NCT02089724 · clinicaltrials.gov ↗
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Groupe Hospitalier Pitie-Salpetriere

Collaborators